iRadimed (NASDAQ:IRMD) Share Price Crosses Above 50-Day Moving Average – Time to Sell?

iRadimed Corporation (NASDAQ:IRMD) shares passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $86.43 and traded as high as $86.55. iRadimed shares last traded at $85.88, with a volume of 91,612 shares changing hands.

Wall Street Analyst Weigh In

IRMD has been the subject of several recent research reports. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 2nd. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC started coverage on shares of iRadimed in a research report on Tuesday, September 22nd. They issued a “hold” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Stock Up 1.8%

The business’s 50-day moving average price is $86.37 and its 200 day moving average price is $90.76. The company has a market capitalization of $1.12 billion, a P/E ratio of 48.86 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 44.69%.

Insider Buying and Selling

In other news, Director Monty K. Allen sold 1,419 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the sale, the director owned 19,581 shares in the company, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 34.60% of the stock is owned by company insiders.

Institutional Trading of iRadimed

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of iRadimed in the 2nd quarter valued at about $92,485,000. Dimensional Fund Advisors LP lifted its holdings in shares of iRadimed by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock valued at $21,768,000 after purchasing an additional 9,017 shares during the last quarter. Ranger Investment Management L.P. purchased a new stake in iRadimed in the second quarter valued at about $9,398,000. Bank of New York Mellon Corp acquired a new stake in iRadimed in the 2nd quarter worth approximately $7,252,000. Finally, Sei Investments Co. raised its holdings in shares of iRadimed by 17.2% in the first quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider’s stock worth $7,153,000 after buying an additional 10,908 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

IRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on addressing the challenges of providing continuous infusion therapy and patient monitoring while patients are undergoing MRI procedures.

Its products include the MRidium MRI-compatible infusion pump system, which is designed to deliver intravenous medications and fluids without interfering with MRI operations, and MRI-compatible patient-monitoring systems used to track vital signs during imaging.